These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19451606)

  • 1. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents.
    Newland AM; Mauro VF; Alexander KS
    Am J Health Syst Pharm; 2009 Jun; 66(11):986-7. PubMed ID: 19451606
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of metoprolol tartrate injection 1 mg/mL undiluted and 0.5 mg/mL in 0.9% sodium chloride injection and 5% dextrose injection.
    Kraft MD; Johnson CE; Chung C; Julian F
    Am J Health Syst Pharm; 2008 Apr; 65(7):636-8. PubMed ID: 18359971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
    Foushee JA; Meredith P; Fox LM; Grace E
    Int J Pharm Compd; 2016; 20(4):328-332. PubMed ID: 28333677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the FT-IR characteristics and metoprolol tartrate release of methylcellulose-based patches.
    Papp J; Horgos J; Szente V; Zelkó R
    Int J Pharm; 2010 Jun; 392(1-2):189-91. PubMed ID: 20371276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compatibility of selected critical care drugs during simulated Y-site administration.
    Yamashita SK; Walker SE; Choudhury T; Iazzetta J
    Am J Health Syst Pharm; 1996 May; 53(9):1048-51. PubMed ID: 8744469
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimization of fluid bed formulations of metoprolol granules and tablets using an experimental design.
    Tomuţă I; Alecu C; Rus LL; Leuçuta SE
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1072-81. PubMed ID: 19353417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative stability of repackaged metoprolol tartrate tablets.
    Yang Y; Gupta A; Carlin AS; Faustino PJ; Lyon RC; Ellison CD; Rothman B; Khan MA
    Int J Pharm; 2010 Jan; 385(1-2):92-7. PubMed ID: 19879937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release floating multiparticulates of metoprolol succinate by hot melt extrusion.
    Malode VN; Paradkar A; Devarajan PV
    Int J Pharm; 2015 Aug; 491(1-2):345-51. PubMed ID: 26142246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of metoprolol tartrate in 5% dextrose injection or 0.9% sodium chloride injection.
    Belliveau PP; Shea BF; Scavone JM
    Am J Hosp Pharm; 1993 May; 50(5):950-2. PubMed ID: 8506875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration.
    Griffith SN; Stapleton E; Padilla S; Mruk A; Thomas CA
    Am J Health Syst Pharm; 2020 Nov; 77(23):1938-1940. PubMed ID: 32991671
    [No Abstract]   [Full Text] [Related]  

  • 11. Visual compatibility of argatroban with selected drugs.
    Hartman CA; Baroletti SA; Churchill WW; Patel P
    Am J Health Syst Pharm; 2002 Sep; 59(18):1784-5. PubMed ID: 12298120
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and characterization of Zwitterionic co-polymers as matrices for sustained metoprolol tartrate delivery.
    Kamenska E; Kostova B; Ivanov I; Rachev D; Georgiev G
    J Biomater Sci Polym Ed; 2009; 20(2):181-97. PubMed ID: 19154669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility of conivaptan injection with select cardiovascular medications.
    Howard MS; Boddu SH; Mauro VF; Churchwell MD
    Am J Health Syst Pharm; 2014 Sep; 71(18):1534-5. PubMed ID: 25174012
    [No Abstract]   [Full Text] [Related]  

  • 14. [Transdermal administration of drugs. XI. Formulation of polymeric matrices with metoprolol in transdermal therapeutic systems].
    Kucera J; Ducková K
    Ceska Slov Farm; 1996 Jul; 45(4):185-90. PubMed ID: 8925241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets.
    Allen LV; Levinson RS; Phisutsinthop D
    Am J Hosp Pharm; 1977 Sep; 34(9):939-43. PubMed ID: 20779
    [No Abstract]   [Full Text] [Related]  

  • 17. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical mechanisms in the radiosterilization of metoprolol tartrate solutions.
    Slegers C; Baldacchino G; Le Parc D; Hickel B; Tilquin B
    Pharm Res; 2003 Dec; 20(12):1977-83. PubMed ID: 14725362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical incompatibility of parenteral drug admixtures.
    McCarthy TJ
    S Afr Med J; 1974 Sep; 48(46):1951-3. PubMed ID: 4421027
    [No Abstract]   [Full Text] [Related]  

  • 20. Eudragit FS based colonic microparticls of metoprolol tartrate.
    Rasool F; Ahmad M; Murtaza G; Khan HM; Khan SA
    Acta Pol Pharm; 2012; 69(2):347-53. PubMed ID: 22568051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.